2013 Cannabinoid Function in the CNS Gordon Research Conference & Gordon Research

描述(由申请人提供)：目前的R13赠款请求支持将于2013年举行的戈登研究会议和戈登研究研讨会(GRC/GRS)，讨论中枢神经系统的大麻功能。我们将利用创新的GRC/GRS模式来实现三个具体目标：1.促进和维持一个科学论坛，以便深入介绍和充分讨论中枢神经系统大麻类药物功能领域的前沿未发表数据。2.为推动下一代科学进步的尖端协作科学创造机会，并将研究大麻素相关神经可塑性的基础研究人员与研究疾病状态下神经可塑性变化的长期影响的临床研究人员联合起来。3.通过戈登研究研讨会促进和指导下一代大麻科学家，同时鼓励大麻领域的多样性和包容性。基于内源性大麻素系统在控制神经元兴奋性方面的关键作用、内源性大麻素失调对疾病状态的贡献、内源性大麻素调节剂的治疗潜力以及娱乐性(如香料)和医用(如Sativex、医用大麻)在人类中日益广泛的使用，联席会议的形式是有必要的。最近出现的以大麻素为基础的药物要求继续把研究重点放在了解大麻素对人类的影响，特别是长期后果(即滥用责任、不良副作用、安全考虑)。大麻素的临床研究没有在之前的任何关于大麻素的戈登研究会议上发表，这要求项目组织者专门接触临床研究人员，这些研究人员通常不会参加专注于基础而不是临床科学的戈登研究会议。因此，GRC的形式为在研究神经可塑性的临床前研究人员和研究以神经可塑性改变为标志的人类疾病状态(例如病理性疼痛、成瘾、神经退行性疾病)的临床研究人员之间建立跨学科科学的桥梁提供了重要机会。戈登研究研讨会(GRS 2013：“神经生理学和神经病理学中的内源性大麻素”)由研究生和博士后研究员组织，并为研究生和博士后研究员举办，被学员高度评价为在学员发展的关键阶段提供指导和网络机会的场所。GRS直接先于GRC(GRC 2013：《突触、回路和人脑》)。R13对2013年GRC-GRS联合会议的支持预计将促进大麻类药物领域多样性的互惠增加。目前的R13赠款预计将促进尖端合作科学的机会，同时确保致力于大麻素研究的高评级GRC继续取得成功和持续发展。

DESCRIPTION (provided by applicant): The present R13 grant requests support for a joint Gordon Research Conference and Gordon Research Seminars (GRC/GRS) on Cannabinoid Function in the CNS to be held in 2013. We will exploit the innovative GRC/GRS format to accomplish three Specific Aims: 1. To promote and sustain a scientific forum that allows for in depth presentation and adequate discussion of cutting edge unpublished data in the area of Cannabinoid Function in the CNS. 2. To foster opportunities for cutting edge collaborative science that propels the next generation of scientific advances and unites basic researchers studying cannabinoid-related neuroplasticity with clinical researchers studying long term impact of altered neuoroplasticity in disease states. 3. To promote and mentor the next generation of cannabinoid scientists while encouraging diversity and inclusiveness in the cannabinoid field through the Gordon Research Seminar. The joint meeting format is warranted based upon the critical role of the endocannabinoid system in controlling neuronal excitability, the contribution f endocannabinoid dysregulation to disease states, the therapeutic potential of endocannabinoid modulators and the increasingly widespread use of both recreational (e.g. spice) and medicinal (e.g. Sativex, medical marijuana) cannabinoids in humans. The recent advent of cannabinoid- based medicines requires that continued research emphasis be placed on understanding cannabinoid effects in humans, especially long-term consequences (i.e. abuse liability, adverse side-effects, safety considerations). Clinical studies of cannabinoids have not been represented at any prior Gordon Research Conference on cannabinoids, mandating that program organizers specifically reach out to clinical researchers that would not typically attend a Gordon Research Conference focused on basic as opposed to clinical science. The format of the GRC thus provides an important opportunity to build bridges in interdisciplinary science between preclinical researchers studying neuroplasticity and clinical researchers studying human disease states marked by altered neuroplasticity (e.g. pathological pain, addiction, neurodegenerative diseases). The Gordon Research Seminar (GRS 2013: "Endocannabinoids in Neurophysiology and Neuropathology") is organized by and for graduate students and post-doctoral fellows and has been highly ranked by trainees as a venue for providing mentoring and networking opportunities at a critical stage of trainee development. The GRS directly precedes the GRC (GRC 2013: "Synapses, Circuits and the Human Brain"). R13 support of the 2013 joint GRC-GRS is expected to promote mutually beneficial increases in diversity in the cannabinoid field. The present R13 grant is expected to foster opportunities for cutting edge collaborative science while ensuring the continued success and sustainability of a highly rated GRC devoted to cannabinoid research.